Phase 3 Evaluation of Oral WD-890 Tablets Versus Placebo for Moderate to Severe Plaque Psoriasis in Adults

What this Trial Is About

Researchers are evaluating an experimental medication called WD-890 compared to a placebo in adults with moderate to severe plaque psoriasis. The study focuses on understanding how well WD-890 works and its safety for treating this skin condition. It is a phase 3 trial involving participants diagnosed with plaque psoriasis for at least six months and meeting certain severity criteria. Participants will be randomly assigned to receive either WD-890 tablets or placebo tablets, both taken orally. The trial is designed as a parallel, double-blind, placebo-controlled study, where neither participants nor researchers know who is receiving which treatment. Treatment and assessments will occur over a period of up to 52 weeks. During the study, participants will be regularly assessed for skin improvement using tools like the Physicians Global Assessment score and Psoriasis Area Severity Index at various weeks up to week 52. Quality of life related to dermatology will also be measured. Safety and treatment effects will be monitored through scheduled visits and evaluations throughout the study period.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis